Abstract 693P
Background
Amivantamab monotherapy in the CHRYSALIS study demonstrated durable responses in advanced non-small cell lung cancer (NSCLC) patients (pts) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins). The objective of the study is to evaluate the effectiveness of amivantamab in CHRYSALIS compared to systemic anti-cancer therapy in Taiwan real-world setting, among advanced NSCLC pts with EGFR ex20ins who received prior-platinum-doublet chemotherapy.
Methods
External control (EC) pts from National Taiwan University Hospital (NTUH) were selected by eligibility criteria in CHRYSALIS. The EC dataset used for indirect comparison includes each line of post-platinum-based chemotherapy treatment. Baseline were adjusted for differences in patient characteristics using the propensity score (PS) average treatment effects on the treated (ATT) method. Outcomes were compared using the weighting generalized estimating equations for objective response rate (ORR), and weighting Cox proportional hazards regression for progression-free survival (PFS) and overall survival (OS). Real-world treatment patterns were analyzed using descriptive statistics.
Results
A total of 114 CHRYSALIS and 44 EC pts (106 lines of treatment) were identified. Patients with smoking history in NTUH was lower (13.6% out of 44 pts) than that of CHRYSALIS (43.0% out of 114 pts). After PS adjustment by ATT, compared to pts in Taiwan, amivantamab-treated pts had significantly improved OS (median 23.1 vs. 7.5 mo.; HR [95% CI] 0.39 [0.23-0.66]; p=0.0005), PFS (median 6.9 vs. 2.3 mo.; HR [95% CI] 0.37 [0.24-0.56], p< 0.0001) and ORR (36.8% vs. 3.0%, OR [95% CI]: 20.69 [7.25-59.06], p< 0.00001). Non-platinum chemo was the major treatment for pts in all lines (84.1%) post-platinum-based chemo, followed by TKIs (50%).
Conclusions
This comparative analysis highlights the clinical burden faced by NSCLC patients with EGFR ex20ins mutations in Taiwan, where there is a lack of effective treatments. Amivantamab presents a promising targeted treatment option for these patients in real-world practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Johnson & Johnson Innovative Medicine.
Funding
Johnson & Johnson Innovative Medicine.
Disclosure
J. Zhuo: Financial Interests, Institutional, Full or part-time Employment: Janssen China R&D Center. E. Chen, S. Wang, J. Hsieh: Financial Interests, Institutional, Full or part-time Employment: Johnson & Johnson Taiwan Ltd. All other authors have declared no conflicts of interest.